The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
AI and market research sampling: battling bots and biases
Introduction and how the sampling industry works The landscape of market research sampling has had to evolve significantly in recent years. AI-driven bots are...